Symplicity G3 Renal Denervation RF Generator
Medtronic, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
The FDA record for P220026/S019 describes a 30-day notice for the Symplicity G3 Renal Denervation RF Generator whose stated purpose is approval for replacement of manufacturing lines and inspection process changes for circuit boards. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager, or supplier. The notice does not specify which lines were replaced, which inspection steps changed, or what validation supported the change.
The identifier ties this action to the original PMA P220026, but this is a manufacturing supplement, not an approval of the whole device system. The source statement gives a reported purpose, not evidence of safety or clinical effectiveness, and the record describes no change to indications. Details on the circuit boards and inspection criteria remain absent from the supplied fields.
FDA approval order statement
approval for replacement of manufacturing lines and inspection process changes for circuit boards in the Symplicity G3 Renal Denervation RF Generator
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220026/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220026 · Original PMA
Symplicity Spyral Renal Denervation System
P220026/S014 · Related supplement
Symplicity Spyral Renal Denervation System
P220026/S019 received
Application receipt date recorded by FDA.
P220026/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Nov 17, 2023 | FDA | |
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220026/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
